Welcome to Drug Design 2014

Drug Design 2014 addressed the latest developments in computational and experimental approaches to fragment- and ligand-based drug design. The conference was aimed at bringing together biologists, chemists and computational scientists from academia and industry to discuss the latest developments and breakthroughs in cutting-edge in silico and experimental drug design approaches:-

> Computational chemistry/molecular modeling
> Fragment binding/selectivity
> Ligand design and binding
> Protein-protein/ligand interaction
> New screening technologies and their practical applications

Keynote Speakers

For regular updates follow the conference on Twitter (@DrugsOxford).

23rd September – Day 1

15.00: Professor Dr Iwan de Esch (Keynote Speaker)
Professor of Biocomputational Chemistry for Drug Innovation, Medicinal Chemistry Department, VU University Amsterdam, Amsterdam, The Netherlands
Development of potent Tbr-PDE inhibitors using fragment- and structure-based drug design approaches

16.00: Dr Andrew Westwell
Reader in Medicinal Chemistry, Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
Designing drugs to tackle unmet medical need in breast cancer

16.30: Refreshment break

9.00: Professor Val Gillet (Keynote Speaker)
Professor of Chemoinformatics and Head of School, University of Sheffield, UK
Development and application of chemoinformatics techniques in the design of novel bioactive compounds (Provisional title)

10.00: Dr David Evans
Eli Lilly
Phenotypic screening design  and deconvolution – large scale target prediction models, and target druggability assessment

10.30: Refreshment break

11.00: Dr Jon Elkins
Structural Genomics Consortium, University of Oxford, Roosevelt Drive, Headington, Oxford, UK
Chemogenomics, kinases and finding new purposes for existing inhibitors

11.30: Dr Andreas Bender
Lecturer for Molecular Informatics, Unilever Centre, Cambridge University, UK
Integrating Chemical and Biological Data Using Computational Methods: From Ligand Design to Mode-of-Action Analysis

12.00: Dr Simone Fulle
Group Leader, BioMed X Innovation Center, Heidelberg, Germany
Are there (yet) untapped protein kinases for drug development? – a druggability assessment of ATP-binding sites

12.30: Dr Paul Finn
CEO, InhibOx Ltd, Oxford, UK, and Professorial Research Fellow, University of Buckingham, UK
Predicting kinase selectivity by a novel combinatorial clustering method

13.00: Lunch

14.00: Dr Colin Groom
Executive Director, The Cambridge Crystallographic Data Centre (CCDC), Union Road, Cambridge, UK
Drug Discovery and Development by Design:  Using the Knowledge from Every Organic Crystal Structure Ever Published

14.30: Dr Alberto Marina
Unidad de Cristalografía de Macromoléculas, Instituto de Biomedicina de Valencia (CSIC), Valencia, Spain
Structure and Fragment Based Drug Design for Two-component Systems

15.00: Professor Rebecca Wade
Professor at Zentrum für Molekulare Biologie (ZMBH), and Group Leader, Molecular and Cellular Modeling Group, HITS, DKFZ-ZMBH Alliance and Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Germany
Modelling of protein-ligand interactions (Provisional title)

15.30: Refreshment break

16.30: Professor Roger Griffin
Professor of Medicinal Chemistry, Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Newcastle upon Tyne, UK
Anticancer Drug Discovery. Inhibitors of PARP1, DNA-PK and Mdm2-p53 Interactions Discovered Through Academia/Industry Collaboration

17.30: Close of Day 2

25th September – Day 3

8.55: Welcome

• Important Dates
• Who Should Attend
• Advisors

• • Register 4-for-3: 10 September 2014
  • Registration Deadline: 22 September 2014
• • Industry: CSOs, Reseach Directors, Team Leaders, Senior and Junior Researchers
  • Academia: Laboratory Heads/Professors, Postdoctoral Scientists, Advanced Graduate Research Students

• Dr Paul Finn
  CEO, InhibOx Ltd, and Professorial Research Fellow, University of Buckingham, UK

  Dr Angelo Pugliese
  Senior Scientist, Cancer Research UK (CRUK) Beatson Institute, Drug Discovery Programme, Glasgow, UK

  Dr Andreas Bender
  Lecturer for Molecular Informatics, Unilever Centre, Cambridge University, UK